Mantle Cell Lymphoma
Conditions
Brief summary
This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.
Detailed description
The drug being tested in this study were combination of VcR-CAP and R-CHOP. Combination of VcR-CAP and R-CHOP is being tested to treat people who had mantle cell lymphoma (MCL). The study enrolled 487 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups in a 1:1 ratio: Treatment Group A (VcR-CAP) Treatment Group B (R-CHOP) The study included a screening phase, a treatment phase, a short-term follow-up phase, and a long-term follow-up phase. The screening phase was up to 28 days (56 days for bone marrow evaluation) prior to randomization. This multi-center trial was conducted worldwide. The total study duration from randomization of the first patient until the last progression-free survival (PFS) event required for the final analysis was expected to be approximately 42 months (24 months for enrollment and 18 months for follow-up) and survival follow-up every 12 weeks until death.
Interventions
DRUGRituximab 375 mg/m^2
Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
DRUGCyclophosphamide 750 mg/m^2
Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
DRUGDoxorubicin 50 mg/m^2
Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
DRUGVELCADE 1.3 mg/m^2
Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
DRUGPrednisone 100 mg/m^2
Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
DRUGVincristine 1.4 mg/m^2
Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
Sponsors
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Millennium Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place) * Diagnosis of mantle cell lymphoma MCL (Stage II, III or IV) as evidenced by lymph node histology and either expression of cyclin D1 (in association with CD20 and CD5) or evidence of t(11;14) translocation, such as by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR). Patients with a diagnosis of Stage I MCL will not be permitted to enter study. \- Paraffin embedded biopsy tissue block (preferably of lymph node origin) must be sent to the central laboratory for confirmation of MCL diagnosis prior to randomization. In China, a paraffin embedded lymph node biopsy tissue block must be sent for central confirmation of sample adequacy, prior to randomization * At least 1 measurable site of disease * No prior therapies for MCL * Not eligible for bone marrow transplantation as assessed by the treating physician (e.g., age or the presence of co-morbid conditions that may have a negative impact on the tolerability to transplantation). * Eastern Cooperative Oncology Group ECOG status ≤2 * Absolute neutrophil count (ANC) ≥1500 cells/µL, * Platelets ≥100,000 cells/µL or ≥75,000 cells/µL if thrombocytopenia is considered by the investigator to be secondary to MCL (e.g., due to bone marrow infiltration or sequestration from splenomegaly). * Alanine transaminase ≤3 x upper limit of normal (ULN) * Aspartate transaminase ≤3 x ULN * Total bilirubin ≤1.5 x ULN, * Calculated creatinine clearance ≥20 mL/min. * Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) and have a negative serum βHCG or urine pregnancy test at screening. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment. * Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. * All patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. * In order to participate in the pharmacogenomics component of this study, patients (or their legally acceptable representative) must have signed the informed consent form for pharmacogenomics research indicating willingness to participate in the pharmacogenomics component of the study. Acquisition of tumor sample collections is required for all patients (where available); all other sample collections are optional
Exclusion criteria
* Prior treatment with VELCADE * Prior antineoplastic (including unconjugated therapeutic antibodies), experimental or radiation therapy, radioimmunoconjugates or toxin immunoconjugates for the treatment of MCL. In the event that a patient has received doxorubicin for the treatment of any condition, other than MCL, the maximum dose and exposure received prior to entry into this study should not exceed 150 mg/m2. \- short course (maximum of 10 days, not exceeding 100 mg/day) prednisone or equivalent steroids are allowed to treat symptoms in patients with advanced disease who enter the screening phase and are waiting to be randomized. * Major surgery (at the discretion of the treating physician and in consultation with the sponsor's medical monitor) within 2 weeks before randomization * Peripheral neuropathy or neuropathic pain of Grade 2 or worse (as per the investigators assessment) * Diagnosed or treated for a malignancy other than MCL within 1 year of randomization, or who were previously diagnosed with a malignancy other than MCL and have any radiographic or biochemical marker evidence of malignancy. Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded. * Active systemic infection requiring treatment and patients with known diagnosis of human immunodeficiency virus HIV or active hepatitis B (carriers of hepatitis B are permitted to enter study) * History of allergic reaction attributable to compounds containing boron, mannitol, or hydroxybenzoates * Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate * Female or male patients of child-bearing potential who will not use adequate contraception during the course of the study. * Serious medical (e.g., pericardial disease, cardiac failure \[New York Heart Association; NYHA Class III or IV, Attachment 12 or left ventricular ejection fraction; LVEF \<50%\], active peptic ulceration, uncontrolled diabetes mellitus, or acute diffuse infiltrative pulmonary disease), or psychiatric illness likely to interfere with participation in this clinical study * Concurrent treatment with another investigational agent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Median duration of follow-up of 40 months | PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | Median duration of follow-up of 40 months | The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH). |
| Time to Next Anti-lymphoma Treatment (TTNT) | : Median duration of follow-up of 40 months | The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive. |
| Treatment-free Interval (TFI) | Median duration of follow-up of 40 months | The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive. |
| Overall Response Rate (ORR) | Median duration of follow-up of 40 months | ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death. |
| Time to Progression (TTP) | Median duration of follow-up of 40 months | Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee. |
| Overall Survival (OS) | Median duration of follow-up of 40 months | OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive. |
| 18-Month Survival | Up to month 18 from the time of randomization | 18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate). |
| Overall Survival (OS) in Long Term Follow-up Period | Up to 107.4 months | OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive. |
| Number of Participants Experiencing an Adverse Event (AE) | Up to 107.4 months | An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug. |
| Overall Complete Response (CR + CRu) | Median duration of follow-up of 40 months | Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death. |
Countries
Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Germany, Hungary, India, Israel, Italy, Malaysia, Morocco, Philippines, Poland, Portugal, Romania, Russia, Singapore, South Africa, Spain, Taiwan, Thailand, Tunisia, Turkey (Türkiye), Ukraine, United States
Participant flow
Recruitment details
A total of 487 participants were randomized from 128 centers in 28 countries from 22 May 2008 to 17 June 2017; 244 to the R-CHOP treatment group and 243 to the VcR-CAP treatment group. Of the 487 randomized participants, 242 in the R-CHOP group and 240 in the VcR-CAP group received at least 1 dose of study drug.
Participants by arm
| Arm | Count |
|---|---|
| R-CHOP Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, Vincristine 1.4 mg/m\^2 and Prednisone 100 mg/m\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles Vincristine: Vincristine intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. | 244 |
| VcR-CAP Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, VELCADE 1.3 mg/m\^2, and Prednisone 100 mg/m\^2 Rituximab: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles. Cyclophosphamide: Cyclophosphamide intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles Doxorubicin: Intravenous on Day of a 21 day (3 week) cycle for 6 cycles VELCADE: VELCADE intravenous on Days 1,4,8, and 11 of a 21 day (3 week) cycle for 6 cycles Prednisone: Prednisone orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles. | 243 |
| Total | 487 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 17 | 21 |
| Overall Study | Death | 12 | 7 |
| Overall Study | Other Reason Unknown | 3 | 4 |
| Overall Study | Overt Disease Progression | 5 | 4 |
| Overall Study | Randomized But Not Treated | 2 | 3 |
| Overall Study | Withdrawal by Subject | 6 | 9 |
Baseline characteristics
| Characteristic | R-CHOP | VcR-CAP | Total |
|---|---|---|---|
| Age, Continuous | 64.4 Years STANDARD_DEVIATION 8.78 | 64.2 Years STANDARD_DEVIATION 9.68 | 64.3 Years STANDARD_DEVIATION 9.23 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 68 Participants | 88 Participants | 156 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 172 Participants | 151 Participants | 323 Participants |
| Region of Enrollment Austria | 6 Participants | 4 Participants | 10 Participants |
| Region of Enrollment Belgium | 10 Participants | 16 Participants | 26 Participants |
| Region of Enrollment Brazil | 9 Participants | 13 Participants | 22 Participants |
| Region of Enrollment Canada | 6 Participants | 1 Participants | 7 Participants |
| Region of Enrollment Chile | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment China | 34 Participants | 61 Participants | 95 Participants |
| Region of Enrollment Colombia | 2 Participants | 3 Participants | 5 Participants |
| Region of Enrollment Czech Republic | 5 Participants | 9 Participants | 14 Participants |
| Region of Enrollment France | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment Germany | 7 Participants | 1 Participants | 8 Participants |
| Region of Enrollment Hungary | 5 Participants | 8 Participants | 13 Participants |
| Region of Enrollment India | 9 Participants | 3 Participants | 12 Participants |
| Region of Enrollment Israel | 5 Participants | 2 Participants | 7 Participants |
| Region of Enrollment Italy | 6 Participants | 3 Participants | 9 Participants |
| Region of Enrollment Japan | 11 Participants | 7 Participants | 18 Participants |
| Region of Enrollment Korea, Republic Of | 2 Participants | 3 Participants | 5 Participants |
| Region of Enrollment Poland | 9 Participants | 10 Participants | 19 Participants |
| Region of Enrollment Portugal | 3 Participants | 4 Participants | 7 Participants |
| Region of Enrollment Romania | 9 Participants | 4 Participants | 13 Participants |
| Region of Enrollment Russia | 57 Participants | 42 Participants | 99 Participants |
| Region of Enrollment Singapore | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment Spain | 8 Participants | 6 Participants | 14 Participants |
| Region of Enrollment Taiwan, Province Of China | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment Thailand | 9 Participants | 10 Participants | 19 Participants |
| Region of Enrollment Tunisia | 3 Participants | 3 Participants | 6 Participants |
| Region of Enrollment Turkey | 5 Participants | 1 Participants | 6 Participants |
| Region of Enrollment Ukraine | 18 Participants | 16 Participants | 34 Participants |
| Region of Enrollment United States | 2 Participants | 5 Participants | 7 Participants |
| Sex: Female, Male Female | 62 Participants | 65 Participants | 127 Participants |
| Sex: Female, Male Male | 182 Participants | 178 Participants | 360 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 187 / 242 | 185 / 240 |
| serious Total, serious adverse events | 72 / 242 | 91 / 240 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.
Time frame: Median duration of follow-up of 40 months
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Progression Free Survival (PFS) | 437.0 Days |
| VcR-CAP | Progression Free Survival (PFS) | 751.0 Days |
p-value: <0.00195% CI: [0.5, 0.79]Log Rank
Secondary
18-Month Survival
18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate).
Time frame: Up to month 18 from the time of randomization
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| R-CHOP | 18-Month Survival | 83.8 Percentage of Participants |
| VcR-CAP | 18-Month Survival | 84.9 Percentage of Participants |
Secondary
Duration of Response
The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH).
Time frame: Median duration of follow-up of 40 months
Population: The response-evaluable population was defined as all participants who received at least 1 dose of study drug, had \>= 1 measurable tumor mass (\>1.5 cm in the longest dimension and \>1.0 cm in the short axis) at baseline and had at least 1 post-baseline tumor assessment by Independent Review Committee, before any subsequent anti-lymphoma treatment.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| R-CHOP | Duration of Response | Duration of response | 459.0 Days |
| R-CHOP | Duration of Response | Duration for Complete responders | 563.0 Days |
| VcR-CAP | Duration of Response | Duration of response | 1110.0 Days |
| VcR-CAP | Duration of Response | Duration for Complete responders | 1282.0 Days |
Secondary
Number of Participants Experiencing an Adverse Event (AE)
An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug.
Time frame: Up to 107.4 months
Population: The safety population was defined as all randomized participants who received at least 1 dose of study medication.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| R-CHOP | Number of Participants Experiencing an Adverse Event (AE) | 239 Participants |
| VcR-CAP | Number of Participants Experiencing an Adverse Event (AE) | 240 Participants |
Secondary
Overall Complete Response (CR + CRu)
Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.
Time frame: Median duration of follow-up of 40 months
Population: The response-evaluable population was defined as all participants who received \>= 1 dose of study drug, had at least 1 measurable tumor mass (\>1.5 cm in the longest dimension and \>1.0 cm in the short axis) at baseline and had at least 1 post-baseline tumor assessment by Independent Review Committee, before any subsequent anti-lymphoma treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| R-CHOP | Overall Complete Response (CR + CRu) | Overall complete response | 95 Participants |
| R-CHOP | Overall Complete Response (CR + CRu) | CR | 79 Participants |
| R-CHOP | Overall Complete Response (CR + CRu) | CRu | 16 Participants |
| VcR-CAP | Overall Complete Response (CR + CRu) | Overall complete response | 122 Participants |
| VcR-CAP | Overall Complete Response (CR + CRu) | CR | 106 Participants |
| VcR-CAP | Overall Complete Response (CR + CRu) | CRu | 16 Participants |
p-value: <0.00795% CI: [1.148, 2.481]Cochran-Mantel-Haenszel Chi-Square
Secondary
Overall Response Rate (ORR)
ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.
Time frame: Median duration of follow-up of 40 months
Population: The response-evaluable population was defined as all participants who received \>= 1 dose of study drug, had at least 1 measurable tumor mass (\>1.5 cm in the longest dimension and \>1.0 cm in the short axis) at baseline and had at least 1 post-baseline tumor assessment by Independent Review Committee, before any subsequent anti-lymphoma treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| R-CHOP | Overall Response Rate (ORR) | 204 Participants |
| VcR-CAP | Overall Response Rate (ORR) | 211 Participants |
p-value: 0.27595% CI: [0.749, 2.722]Cochran-Mantel-Haenszel Chi-Square
Secondary
Overall Survival (OS)
OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.
Time frame: Median duration of follow-up of 40 months
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Overall Survival (OS) | 1714.0 Days |
| VcR-CAP | Overall Survival (OS) | NA Days |
p-value: 0.17395% CI: [0.59, 1.1]Log Rank
Secondary
Overall Survival (OS) in Long Term Follow-up Period
OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.
Time frame: Up to 107.4 months
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Overall Survival (OS) in Long Term Follow-up Period | 1695.0 Days |
| VcR-CAP | Overall Survival (OS) in Long Term Follow-up Period | 2760.0 Days |
Secondary
Time to Next Anti-lymphoma Treatment (TTNT)
The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive.
Time frame: : Median duration of follow-up of 40 months
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Time to Next Anti-lymphoma Treatment (TTNT) | 756.0 Days |
| VcR-CAP | Time to Next Anti-lymphoma Treatment (TTNT) | 1353.0 Days |
p-value: <0.00195% CI: [0.38, 0.65]Log Rank
Secondary
Time to Progression (TTP)
Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee.
Time frame: Median duration of follow-up of 40 months
Population: The population consisted of all randomized participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Time to Progression (TTP) | 490.0 Days |
| VcR-CAP | Time to Progression (TTP) | 929.0 Days |
p-value: <0.00195% CI: [0.45, 0.74]Log Rank
Secondary
Treatment-free Interval (TFI)
The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive.
Time frame: Median duration of follow-up of 40 months
Population: All randomized participants who received at least 1 dose of study medication.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-CHOP | Treatment-free Interval (TFI) | 624.0 Days |
| VcR-CAP | Treatment-free Interval (TFI) | 1236.0 Days |
p-value: =0.00195% CI: [0.38, 0.65]Log Rank